

Important Notice Regarding the Fund: The fund's underlying benchmark index was changed on March 17, 2023. Please see the fund's prospectus on ProFunds.com for more information. The data presented herein is reflective of the fund's new benchmark as of 03/31/23.



FACT SHEET As of 3/31/23

HEALTH CARE ULTRASECTOR PROFUND

Fund objective

Health Care UltraSector ProFund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the S&P Health Care Select SectorSM Index. The Fund does not seek to achieve its stated investment objective over a period of time greater than a single day.

Fund details

Inception Date	06/19/2000
Investor Class Symbol	HCPIX
Service Class Symbol	HCPSX
Investor Class Cusip	743185373
Service Class Cusip	743185365
Investor Class Gross Expense Ratio	1.73%
Service Class Gross Expense Ratio	2.73%
Investor Class Net Expense Ratio ¹	1.73%
Service Class Net Expense Ratio ¹	2.73%
Limit on Exchange	None

Uses for magnified exposure

Common uses for magnified exposure include:

- Seeking magnified gains (will also magnify losses)
- Getting a target level of exposure for less cash
- Overweighting a market segment without additional cash


Fund performance and index history²

The Health Care UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the S&P Health Care Select Sector IndexSM Index (the "Index") for a single day, not for any other period.

	1Q 2023	Year to Date	1-Year	5-Year	10-Year	Fund Inception
Investor Class NAV Total Return	-6.84%	-6.84%	-10.99%	12.40%	15.40%	7.71%
Service Class NAV Total Return	-7.08%	-7.08%	-11.88%	11.30%	14.27%	6.67%
S&P Health Care Select Sector	-4.31%	-4.31%	-3.70%	11.81%	12.87%	—
Dow Jones U.S. Health Care	-3.79%	-3.79%	-4.45%	11.30%	12.79%	8.33%

Periods greater than one year are annualized.

Daily return during 1Q 2023



Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Performance data current to the most recent month-end is available at Profunds.com or by calling 1-888-776-3637.

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

¹Contractual waiver effective until November 30, 2023. Without such a waiver of fees, the total returns would have been lower.

²All data, unless otherwise noted, is as of 3/31/23, and for Investor Class Shares only. Holdings and other data are subject to change.

Index description ²																																			
<p>The Index represents the health care sector of the S&P 500 Index ("S&P 500"). The Index is one of eleven S&P Select Sector Indices, each designed to measure the performance of a sector of the S&P 500. The Index includes equity securities of companies from the following Global Industry Classification Standard (GICS®) industries: health care equipment & supplies, health care providers & services; health care technology; biotechnology; pharmaceuticals; and life sciences tools & services.</p>	<div> <div> Top index companies ² <table> <thead> <tr> <th></th><th>Weights</th></tr> </thead> <tbody> <tr><td>UnitedHealth Group Inc.</td><td>9.06%</td></tr> <tr><td>Johnson & Johnson</td><td>8.31%</td></tr> <tr><td>AbbVie Inc.</td><td>5.78%</td></tr> <tr><td>Eli Lilly & Co.</td><td>5.55%</td></tr> <tr><td>Merck & Co. Inc.</td><td>5.53%</td></tr> <tr><td>Pfizer Inc.</td><td>4.70%</td></tr> <tr><td>Thermo Fisher Scientific Inc.</td><td>4.64%</td></tr> <tr><td>Abbott Laboratories</td><td>3.62%</td></tr> <tr><td>Danaher Corp.</td><td>3.39%</td></tr> <tr><td>Bristol-Myers Squibb Co.</td><td>3.02%</td></tr> </tbody> </table> </div> <div> Index sectors ² <table> <thead> <tr> <th></th><th>Weights³</th></tr> </thead> <tbody> <tr><td>Pharmaceuticals</td><td>29.31%</td></tr> <tr><td>Health Care Providers & Services</td><td>21.41%</td></tr> <tr><td>Health Care Equipment & Supplies</td><td>20.15%</td></tr> <tr><td>Biotechnology</td><td>16.16%</td></tr> <tr><td>Life Sciences Tools & Services</td><td>12.97%</td></tr> </tbody> </table> </div> <div> </div> </div>		Weights	UnitedHealth Group Inc.	9.06%	Johnson & Johnson	8.31%	AbbVie Inc.	5.78%	Eli Lilly & Co.	5.55%	Merck & Co. Inc.	5.53%	Pfizer Inc.	4.70%	Thermo Fisher Scientific Inc.	4.64%	Abbott Laboratories	3.62%	Danaher Corp.	3.39%	Bristol-Myers Squibb Co.	3.02%		Weights ³	Pharmaceuticals	29.31%	Health Care Providers & Services	21.41%	Health Care Equipment & Supplies	20.15%	Biotechnology	16.16%	Life Sciences Tools & Services	12.97%
	Weights																																		
UnitedHealth Group Inc.	9.06%																																		
Johnson & Johnson	8.31%																																		
AbbVie Inc.	5.78%																																		
Eli Lilly & Co.	5.55%																																		
Merck & Co. Inc.	5.53%																																		
Pfizer Inc.	4.70%																																		
Thermo Fisher Scientific Inc.	4.64%																																		
Abbott Laboratories	3.62%																																		
Danaher Corp.	3.39%																																		
Bristol-Myers Squibb Co.	3.02%																																		
	Weights ³																																		
Pharmaceuticals	29.31%																																		
Health Care Providers & Services	21.41%																																		
Health Care Equipment & Supplies	20.15%																																		
Biotechnology	16.16%																																		
Life Sciences Tools & Services	12.97%																																		
Index Characteristics ²																																			
<table> <tbody> <tr><td>Number of Companies</td><td>65</td></tr> <tr><td>Price/Earnings Ratio</td><td>15.78</td></tr> <tr><td>Price/Book Ratio</td><td>4.68</td></tr> <tr><td>Dividend Yield</td><td>1.67%</td></tr> <tr><td>Average Market Cap</td><td>\$77.10 billion</td></tr> </tbody> </table>	Number of Companies	65	Price/Earnings Ratio	15.78	Price/Book Ratio	4.68	Dividend Yield	1.67%	Average Market Cap	\$77.10 billion																									
Number of Companies	65																																		
Price/Earnings Ratio	15.78																																		
Price/Book Ratio	4.68																																		
Dividend Yield	1.67%																																		
Average Market Cap	\$77.10 billion																																		
<p>For more information, visit Profunds.com or ask your financial advisor or broker.</p>																																			

Narrowly focused investments typically exhibit higher volatility.

Many ProFunds routinely employ leveraged investment techniques that magnify gains and losses, and result in greater volatility in value. Each geared (leveraged or inverse) ProFund seeks a return that is a multiple (e.g., 2x, -1x) of the return of an index or other benchmark (target) **for a single day**. Due to the compounding of daily returns, geared ProFunds' returns over periods other than one day will likely differ in amount and possibly direction from the target return for the same period. These effects may be more pronounced in funds with larger or inverse multiples and in funds with volatile benchmarks. Investors should monitor their ProFunds holdings consistent with their strategies, as frequently as daily. For more on risks, please read the prospectus.

ProFunds are not suitable for all investors because of the sophisticated techniques the funds employ. Investing involves risk, including the possible loss of principal. ProFunds entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance, all of which can increase volatility and decrease performance. For more on correlation, leverage and other risks, please read the prospectus. There is no guarantee any ProFund will achieve its investment objective.

All ProFunds are subject to active investor risk. There are no restrictions on the size and frequency of trades and no transaction fees. The frequent exchanges our policies permit can decrease performance, increase expenses and cause investors to incur tax consequences.

Carefully consider the investment objectives, risks, charges and expenses of ProFunds before investing. A prospectus or summary prospectus with this and other information may be obtained at Profunds.com or by calling 1-888-776-3637. Read them carefully before investing.

³Sum of weightings may not equal 100% due to rounding.

ProFunds are distributed by ProFunds Distributors Inc.© 2023